K-Duo Sustained-Release Tablet 5/500 mg
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
KS Pharmaceutical Co., Ltd.
MFDS item code 202204061 · Approved 2022.11.10
Improves glycemic control in adults with type 2 diabetes mellitus
This medication is used to enhance blood glucose control in adults with type 2 diabetes by combining dapagliflozin and metformin. It is administered as an adjunct to diet and exercise therapy to provide more effective blood glucose management. Particularly, in patients whose blood glucose is not sufficiently controlled and who have cardiovascular disease or risk factors, reference should be made to expert guidelines regarding the cardiovascular effects of dapagliflozin. This medication aids in maintaining safe and effective blood glucose control while also supporting cardiovascular health.
The dose of this drug should be individualized based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended doses of dapagliflozin 10mg and extended-release metformin 2000mg. This drug is generally administered once daily with the evening meal. The maximum dose of this drug is dapagliflozin 10mg/extended-release metformin 2000mg once daily, administered as 2 tablets of 5mg/1000mg. Patients who have not previously received antidiabetic drug therapy and for whom adequate glycemic control is difficult to achieve with monotherapy: When used as initial therapy in patients who have not previously received antidiabetic drug therapy, the recommended starting dose of this drug is 1 tablet of 5mg/500mg or 10mg/500mg once daily. The dose should be increased gradually to reduce gastrointestinal adverse reactions associated with metformin. For patients receiving metformin, the recommended dose of dapagliflozin is 10mg once daily, and the dose of this drug should provide the same or a therapeutically appropriate dose of metformin as the dose the patient was taking. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dosage adjusted appropriately. For patients switching from combination therapy with dapagliflozin and metformin to this drug, the dose of this drug may be started at the doses of dapagliflozin and metformin previously administered. When switching from immediate-release to extended-release metformin, glycemic control should be closely monitored and the dosage adjusted appropriately. When this drug is used in combination with insulin or an insulin secretagogue such as a sulfonylurea, a lower dose of insulin or the insulin secretagogue may be considered to reduce the risk of hypoglycemia. The safety and efficacy of this drug have not been specifically evaluated in patients switching from other antihyperglycemic agents. Since a change may cause changes in glycemic control, any change in the treatment of patients with type 2 diabetes mellitus should be made with careful monitoring. This drug must be swallowed whole and must never be crushed, cut, or chewed. Occasionally, the inactive ingredients of this drug may be excreted in the stool as a soft, hydrated mass resembling a tablet. Renal impairment No dosage adjustment is necessary in patients with mild renal impairment. For patients with an estimated glomerular filtration rate (eGFR) of 45 mL/min/1.73 m2 or more and less than 60 mL/min/1.73 m2, and who have no other symptoms that may increase the risk of lactic acidosis, the starting dose of metformin hydrochloride, an ingredient of this drug, is 500mg once daily, and the maximum daily dose is 1000mg. Use of this drug is not recommended in patients with an eGFR of less than 45 mL/min/1.73m2. If the estimated glomerular filtration rate (eGFR) falls below 45 mL/min/1.73m2, treatment with this drug must be discontinued immediately. Renal function should be assessed every 3~6 months. Older adults Since metformin is excreted through the kidneys and renal function is more likely to be reduced in older adults, this drug should be used with caution as age increases (see Precautions for Use, 9. Administration to Older Adults, Patient Subsection).
This medication can very rarely cause a serious metabolic complication known as lactic acidosis. Lactic acidosis is a condition where there is a high level of lactate in the blood and an increase in acidity, which can be life-threatening. Caution should be exercised when using this medication in combination with other diabetes treatments like insulin or sulfonylureas, as there is a risk of hypoglycemia. This medication should not be administered to patients with moderate to severe renal impairment, dehydration, serious infections, or cardiovascular issues. It should also be avoided in pregnant or nursing women. Patients undergoing dialysis or suspected of acute renal injury should not use this medication. Patients with decreased fluid volume or renal problems should thoroughly evaluate their condition before administering this medication, and blood pressure and renal function should be monitored periodically during treatment. Special caution is required for patients with low blood pressure, those taking diuretics, and the elderly due to the risk of hypotension or dehydration. This medication can increase the risk of genital and urinary infections, so immediate treatment is necessary if infection symptoms appear. Vitamin B12 levels may drop, therefore, patients taking this medication for long periods should have regular Vitamin B12 tests. Excessive alcohol intake can increase the risk of side effects from this medication, therefore, heavy drinking should be avoided. While taking this medication, abrupt surgery or examinations using iodinated contrast agents should be stopped for a certain period, and treatment should only resume after confirming that renal function is normal. Elderly patients are at a higher risk for reduced renal function, making dose adjustment and monitoring of renal function important. In case of overdose, appropriate symptomatic treatment is required, and for the metformin component, removal can be achieved through hemodialysis. This medication has not established safety and efficacy in children, so it should not be used in this population. Patients should be cautious, as dizziness and other symptoms may occur when driving or operating machinery. Lastly, this medication should be stored in its original container and kept in a safe place out of the reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to prevent air or moisture intrusion, and it is recommended to keep it at room temperature between 1 and 30 degrees Celsius. Storing in this manner helps maintain the effectiveness of the medication for a longer time.
Orange, biconvex, egg-shaped film-coated tablet
30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
KS Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK Inno.N Co., Ltd.
CombinationDapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
HK inno.N Co., Ltd.
Dapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Poonglim Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Punglim Muhak Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
Dapagliflozin citric acid 7.35mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Korea Prime Pharmaceutical Co., Ltd.
CombinationDapagliflozin citric acid 14.7mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
KS Pharm Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.